Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hengrui Therapeutics Inc.

www.hengruitherapeutics.com

Latest From Hengrui Therapeutics Inc.

Asia Deal Watch: BeiGene And Celgene Exit Their Anti-PD-1 Collaboration

The Chinese firm regains all rights to tislelizumab ahead of the closing of Celgene’s merger with Bristol-Myers Squibb. BeiGene also forms cancer JV with US biotech SpringWorks.

Deals Asia Pacific

Asia Executives To Watch: Takeda China GM To Depart, Japan Has New MHLW Minister

Another China GM is leaving. Meanwhile, Japan has a new Minister of Health, Labor and Welfare, and China FDA gets a new deputy commissioner.

Appointments China

Chi-Med Roll Continues With Positive Fruquintinib Phase III Data

Chi-Med's China-focused strategy is paying off with positive Phase III top-line results for its home-grown VEGF inhibitor fruquintinib, keeping it on track to for a filing this year. But competition looms.

Clinical Trials Research & Development

Early Stage Biopharma Financings Kept Up Multibillion-Dollar Pace In 2016

Series A venture capital and seed funding rounds for biopharma firms in 2016 kept pace with the level of investment seen in 2015, excluding one major deal in 2015, laying the foundation for optimism regarding early-stage financings in 2017 for particularly innovative companies.

Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Hengrui Therapeutics Inc.
  • Senior Management
  • Adam Zong, PhD, Pres. & CEO
    Frank G Renshaw, MD, Exec. Dir., Clinical Research
    Weimin Tang, PhD, Exec. Dir., Global Bus. Dev. & Licensing
  • Contact Info
  • Hengrui Therapeutics Inc.
    Phone: (609) 423-2155
    506 Carnegie Ctr.
    Ste. 102
    Princeton, NJ 08540
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register